Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00499031
Other study ID # GOG-0227E
Secondary ID NCI-2009-00596BM
Status Completed
Phase Phase 2
First received July 10, 2007
Last updated December 29, 2014
Start date June 2007

Study information

Verified date December 2014
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.


Description:

PRIMARY OBJECTIVES:

I. To assess the activity of cetuximab for patients with persistent or recurrent carcinoma of the cervix.

II. To determine the frequency of patients who survive progression-free for at least 6 months after initiating therapy or have objective tumor response.

SECONDARY OBJECTIVES:

I. To characterize the distribution of progression-free survival and overall survival.

II. To determine the effect of cetuximab on the duration of objective response in persistent or recurrent carcinoma of the cervix.

III. To determine the nature and degree of toxicity of cetuximab as assessed by CTCAE v3.0 in this cohort of patients.

OUTLINE:

Patients receive cetuximab IV over 120 minutes on day 1. Courses repeat once weekly in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed (with physical exams and histories) every three months for the first two years and then every six months for the next three years.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Inclusion criteria:

- Patients must have persistent or recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression (disease not amenable to curative therapy)

- Histologic documentation of the original primary tumor is required via the pathology report

- All patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded)

- Each lesion must be = 20 mm when measured by conventional techniques, including palpation, plain x-ray, CT scan, and MRI, OR = 10 mm when measured by spiral CT scan

- Patients must have at least one target lesion to be used to assess response on this protocol

- Tumors within a previously irradiated field will be designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy

- Patients must have had one prior systemic chemotherapeutic regimen for management of advanced, metastatic, or recurrent carcinoma of the cervix

- Chemotherapy administered in conjunction with primary radiation as a radiosensitizer is not counted as a systemic chemotherapy regimen

- Patients must not be eligible for a higher priority GOG protocol, if one exists

- In general, this would refer to any active GOG phase III protocol for the same patient population

- Exclusion criteria:

- Patients with craniospinal metastases

- Inclusion criteria:

- Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2 or patients who have received two prior regimens must have a GOG performance status of 0 or 1

- Patients should be free of active infection requiring antibiotics

- Platelet count = 100,000/µl

- ANC = 1,500/µl

- Creatinine = 1.5 x institutional upper limit normal (ULN)

- Bilirubin = 1.5 x ULN

- SGOT and alkaline phosphatase = 2.5 x ULN

- Neuropathy (sensory and motor) = CTCAE v3.0 grade 1

- Calcium < 11.0 mg/dL

- Patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least two months following completion of protocol therapy

- Exclusion criteria:

- Patients with a history of other invasive malignancies, with the exception of nonmelanoma skin cancer and other specific malignancies, are excluded if there is any evidence of other malignancy being present within the last five years

- Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy

- Patients who have a significant history of cardiac disease (i.e., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmias) within 6 months of registration

- Patients who have an uncontrolled seizure disorder or active neurological disease

- Patients known to be seropositive for HIV and active hepatitis, even if liver function studies are in the eligible range

- Pregnant or nursing women or women of childbearing potential unless using effective contraception as determined by the investigator

- Known hemorrhagic diathesis or active bleeding disorder

- Inclusion criteria:

- Recovery from effects of recent surgery, radiotherapy, or chemotherapy

- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration (continuation of hormone replacement therapy is permitted)

- Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration

- Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent cervical disease according to the following definition:

- Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa

- Patients must not have received any non-cytotoxic therapy for management of recurrent or persistent cervical disease

- Patients must not be receiving any other investigational agent

- Exclusion criteria:

- Patients who have received prior therapy with cetuximab or any other anti-epidermal growth factor receptor antibody

- Patients who have received any prior therapy with a tyrosine kinase inhibitor that targets the EGFR pathway

- Patients who have received prior chimerized or murine monoclonal antibody therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of cervical cancer within the last five years are excluded

- Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of cervical cancer within the last five years are excluded

- Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration and that the patient remains free of recurrent or metastatic disease

- Patients who have undergone major surgery, excluding diagnostic biopsy, within 30 days (to allow for full recovery) prior to registration

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
Cetuximab
Given IV

Locations

Country Name City State
United States Abington Memorial Hospital Abington Pennsylvania
United States Akron General Medical Center Akron Ohio
United States AnMed Health Hospital Anderson South Carolina
United States Colorado Gynecologic Oncology Group Aurora Colorado
United States Island Gynecologic Oncology Brightwaters New York
United States University of North Carolina Chapel Hill North Carolina
United States Carolinas Medical Center Charlotte North Carolina
United States MetroHealth Medical Center Cleveland Ohio
United States Riverside Methodist Hospital Columbus Ohio
United States Decatur Memorial Hospital Decatur Illinois
United States M D Anderson Cancer Center Houston Texas
United States Saint Vincent Hospital and Health Services Indianapolis Indiana
United States Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin
United States The Hospital of Central Connecticut New Britain Connecticut
United States Memorial Sloan-Kettering Cancer Center New York New York
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Singing River Hospital Pascagoula Mississippi
United States Women and Infants Hospital Providence Rhode Island
United States CoxHealth South Hospital Springfield Missouri
United States Stony Brook University Medical Center Stony Brook New York
United States Cancer Care Associates-Midtown Tulsa Oklahoma
United States Tulsa Cancer Institute Tulsa Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival Greater Than 6 Months At 6 months No
Primary Objective Tumor Response Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Response is measured according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0):
Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.
Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD.
Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Stable Disease is any condition not meeting the above criteria.
Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease.
every other cycle for the first 6 months; then every 3 months x 2; then every 6 months No
Secondary Duration of Progression-free Survival From study entry until disease progression, death or date of last contact, up to 5 years No
Secondary Duration of Objective Response Rate Up to 5 years No
Secondary Frequency and Severity of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0 Up to 5 years Yes
Secondary Duration of Overall Survival From study entry to death or the date of last contact, up to 5 years No
See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Recruiting NCT04574635 - Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03439085 - DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Recruiting NCT05290935 - Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Phase 2
Recruiting NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer Phase 2
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT00041093 - Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2